Short interest for Immutep gives investors a sense of the degree to which investors are betting on the decline of Immutep's stock. Short interest data is updated every two weeks.

Immutep Stock (NASDAQ:IMMP), Short Interest Report

Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

cancer

Biotech

News

Health Care

Movers

Trading Ideas

General

IMMP

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall response rate was observed in the Phase 2/3 trial.

Cancer Focused Immutep&#39;s Stock Soars On Tuesday - Here&#39;s Why

Equities

Penny Stocks

Markets

Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting

Immutep Limited - American Depositary Shares

Immutep Ltd

In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Immutep Ltd (PRRUF – Research Report), with a price target of ...

Immutep Ltd (PRRUF) Gets a Buy from Bell Potter

Immutep (IMMP) has released an update. Immutep Limited has partnered with the Centre for Human Drug Research to conduct a pioneering Phase I study ...

Immutep Advances Novel Autoimmune Therapy with Phase I Trial

In a report released on April 19, Melissa Benson from Wilsons maintained a Buy rating on Immutep Ltd (PRRUF – Research Report), with a price target...

Wilsons Sticks to Its Buy Rating for Immutep Ltd (PRRUF)

Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers

Immutep reports promising efti/Keytruda data for head and neck cancer

Immutep (IMMP) has released an update. Immutep Limited reports promising preliminary results from the Phase IIb TACTI-003 trial, showing a 26.9% re...

Immutep's Efti Shows Promise in Cancer Trial

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), with a price target of...

Immutep Buy Rating Justified by Strong Clinical Trial Results and Promising Future Prospects

Analyst Joel Beatty from Robert W. Baird maintained a Buy rating on Immutep (IMMP – Research Report) and keeping the price target at $7.00. Joel Be...

Immutep's Efti Shows Promise in Cancer Therapy, Analyst Maintains Buy Rating

Immutep (IMMP) has released an update. Immutep Limited, a biotech firm, has reported promising clinical trial outcomes for efti in metastatic breas...

Immutep Shares Upbeat Clinical Trials Update

Immutep: Realizing The Expected Catalysts, With More To Come

BACK

CAPR

CYCC

FNCH

MLEC

NIVF

PRRUF

WINT

Press Releases

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep Quarterly Activities Report Q2 FY24

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Quarterly Activities Report Q3 FY24

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Akebia Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Immutep Stock (NASDAQ:IMMP), Short Interest Report

People Also Watch